The Metabolomic Discoveries Scientific Advisory Board is made up of a team of leading experts in the field of metabolomics and several applied research disciplines. Their mission is to support Metabolomic Discoveries data interpretation approaches and provide feedback on the technological and biomarker strategies of the company.
The composition of the Scientific Advisory Board:
Prof. Dr. Eckhard Boles
Eckhard Boles studied biology in Cologne and did his PhD in Darmstadt in 1994 in the area of yeast physiology. Then he moved to the University of Düsseldorf where he worked on sugar uptake in yeasts. In 2002 he moved to the University of Frankfurt as a full professor for microbiology. In 2011 he became full professor for Physiology and Genetics of lower Eukaryotes. Large parts of his research interests are devoted to the biotechnological optimization of yeasts to produce chemical molecules. Eckhard is co-founder of two companies in the area of bioenergy and biofuels. He has over 100 peer-reviewed publications.
Prof. Dr. Mark Stitt
Mark Stitt is the director of the department metabolic networks at the Max-Planck-Institute of Molecular Plant Physiology, Potsdam-Golm, Germany. He did his PhD in the laboratory of Tom ap Rees. In 1978 he moved to Germany, where he worked as a PostDoc in the group of Hans Heldt in Munich. He was appointed Associate Professor for Plant Biochemistry at University of Bayreuth in 1986, and then moved in 1991 to the University of Heidelberg, where he was Full Professor and Director of the Botany Institute. In 2000, he became Director at the Max Planck Institute of Molecular Plant Physiology, Golm. Marks research mission is to carry out a system oriented approach in order to understand the synthesis and regulation of metabolites that are important for storage, transport, adaptation and signaling in plants. In 2008 he was awarded an Honorary Doctorate by the University of Umea, Sweden, and in 2009 was elected to the Leopoldina National Academy of Science. Mark has over 300 peer-reviewed publications.
Dr. Thomas Wilckens
Thomas Wilckens is a medical doctor and a serial entrepreneur. Thomas obtained his MD at the Ludwig-Maximilian University in Munich. He started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Thomas is convinced that we will see a disruption of current therapeutic concepts and related businesses. His current focus is the convergence of multi-omics technologies with real-world clinical data to enable Precision Medicine. He currently develops this approach into the venture InnVentis.